Making the case for EGFR TKI sequencing in mutation-positive NSCLC: a GioTag study US patient analysis.

To assess time-to-treatment failure (TTF) in US patients with mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib-osimertinib treatment in the global, observational GioTag study. Patients had T790M mutation-positive disease after first-line afatinib and subsequently received osimertinib. The primary outcome was TTF. In 129 patients at US centers, median TTF was 28.4 months (90% CI: 27.0-34.1). Median overall survival was 47.6 months (90% CI: 35.5-51.5). Sequential afatinib-osimertinib in this US-treated population was associated with long median TTF and represents an effective, evidence-based treatment option for US patients with mutation-positive NSCLC not presenting with active brain metastases or T790M. : NCT03370770 (ClinicalTrials.gov).